Post by Life Sciences Acceleration Alliance

Europe says it wants to be a global leader in life sciences.   But what message does it send when one of the world's largest pharmaceutical companies decides to cut a major investment in Germany by half?   Eli Lilly has reportedly reduced its planned investment in Germany from €2.3 billion and significantly scaled back the project, citing concerns about the policy environment for pharmaceutical innovation.   This should be a wake-up call.   Across Europe, governments regularly emphasize the importance of biotechnology, innovation, strategic autonomy, and economic competitiveness. At the same time, however, pricing pressure, cost-containment measures, and increasing regulatory uncertainty continue to undermine the business case for investing in innovative medicines. Investors, entrepreneurs, and global companies pay attention to these signals.   Innovation does not disappear when incentives weaken - it moves elsewhere.   Europe still has exceptional scientific talent and a strong research base. But science alone is not enough. Without framework conditions that reward innovation and provide long-term predictability, investment, manufacturing, and future growth will increasingly flow to other regions.   The reduction of a multi-billion-euro investment project should not be viewed as an isolated event. It raises a broader question:   Can Europe realistically aspire to lead in life sciences while simultaneously making itself a less attractive place to invest? https://lnkd.in/eB9ThEiG